NR1H4 and Obesity: Clinical trials are on the way using FXR modulators in chronic liver diseases such as primary biliary cholangitis, in cholestasis, nonalcoholic steatohepatitis (NASH), obesity, metabolic syndrome, hypertriglyceridemia, lipodystrophy.